This high blood pressure drug may reduce alcohol withdrawal symptoms

Credit: CC0 Public Domain

In a new study, researchers found that a drug once used to treat high blood pressure can help alcoholics with withdrawal symptoms reduce or eliminate their drinking.

The research was conducted by a team at Yale University.

There has been no treatment readily available for people who experience severe withdrawal symptoms and these are the people at highest risk of relapse and are most likely to end up in hospital emergency rooms.

Prazosin was originally developed to treat high blood pressure and is still used to treat prostate problems in men, among other conditions.

Previous studies conducted at Yale had shown that the drug works on stress centers in the brain and helps to improve working memory and curb anxiety and craving.

In the study, researchers gave the drug prazosin or a placebo to 100 people entering outpatient treatment after being diagnosed with alcohol use disorder.

All of the patients had experienced varying degrees of withdrawal symptoms prior to entering treatment.

According to the researchers, people with more severe symptoms—including shakes, heightened cravings and anxiety, and difficulty sleeping—who received prazosin significantly reduced the number of heavy drinking episodes and days they drank compared to those who received a placebo.

The drug had little effect on those with few or no withdrawal symptoms.

The team says that stress centers of the brain are severely disrupted early in recovery, especially for those with withdrawal symptoms and high cravings, but that the disruption decreases the longer the person maintains sobriety.

Prazosin could help bridge that gap by moderating cravings and withdrawal symptoms earlier in recovery and increasing the chances that patients refrain from drinking.

One drawback is that in its current form prazosin needs to be administered three times daily to be effective, Sinha noted.

One author of the study is Rajita Sinha, a professor of neuroscience.

The study is published in the American Journal of Psychiatry.

Copyright © 2020 Knowridge Science Report. All rights reserved.